What benefits are associated with Ipamorelin?

Ipamorelin is studied for: selective GH release without cortisol or prolactin co-stimulation, pulsatile GH secretion — synergistic with CJC-1295 in combination protocols, lean mass support and fat metabolism via GH/IGF-1 axis modulation, subcutaneous injection 100–300 mcg; minimal receptor desensitization vs other GHRPs. This reflects the research literature catalogued on PeptideBase — educational only, not medical advice.

Educational use only — not medical advice

Research library

Ipamorelin benefits

From the PeptideBase research library. Educational only — not medical advice.

Studied effects

selective GH release without cortisol or prolactin co-stimulation
pulsatile GH secretion — synergistic with CJC-1295 in combination protocols
lean mass support and fat metabolism via GH/IGF-1 axis modulation
subcutaneous injection 100–300 mcg; minimal receptor desensitization vs other GHRPs

Mechanism

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.